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Abstract 
Dihydrofolate reductase (DHFR) has an important function in folic analogues biosynthesis which is used as nutrition for cells. In a 
specific cancer cell, DHFR has bigger expression than normal cells therefore it is good candidates as target to cancer chemotherap. In this 
research the screening have been done to 10-N-(4’-bromobenzoyl) folic acid and 10-N-(p-toluoyl) folic acid by in silico method. The result 
of molecular docking shows that those two compounds have more stable interaction than other DHFR inhibitors (methotrexate) but those 
two compound do not follow the Lipinsky’s rule of 5 which is affected to its bioavailability. 
Keywords: Cancer, DHFR, In-silico, Folate analogues 
 
Received 26 April 2016; Accepted 19 September 2016 
 
                                                          
*Corresponding author. Tel.: +6231-8280967 
E-mail: siswandono@unair.ac.id 
      DOI: 10.21752/sjppi-ukm/se/a19092016 
1. Introduction 
Cancer is cell which has uncontrollable growth rate and 
spread to another part of the body [1]. About 28.8 million 
people in the world is diagnosed cancer and 7.6 million 
died because of cancer in 2008 [2]. 
There is several enzyme which can be used as target for 
cancer chemotherapy such as ribonucleotide (RNR), 
timidilat sintase (TS) and dihidrofolate reductase (DHFR). 
DHFR contribute in de novo synthesis of timidilic acid and 
purin nucleotide thus these two compounds then becomes 
guanosine triphospate (GTP) which is important for cell 
cycle [3]. When DHFR is inhibited, it could hinder DNA 
and RNA synthesis then could cause in cell death. 
Methotrexate is commercially available drug that can be 
used as cancer treatment and belong to folate analogues 
that can inhibit DHFR but this compound has several 
adverse effect such as anemia megaloblastic and neurotoxic 
[4]. Thus, we need a safer treatment for patient with cancer. 
In this research, we did an in silico study of 2 folate 
analogues; 10-N-(4’-bromobenzoyl) folic acid and 10-N-
(p-toluoyl)folic acid; as potentially cancer therapy and 
comparving them with methotrexate. We also assessing the 
bioavailability of those compound so it could be used 
orally. 
2. Method 
2.1. Target identification 
Docking target for this research is dihydrofolate 
reductase (e.c.1.5.1.3) complexed with methotrexate (Fig. 1 
PDBID – 1DDS) and was downloaded from RSCB Protein 
Data Bank (http://www.rcsb.org/). 1DDS is chosen because 
it contains methotrexate, which is commercially available 
medicine against cancer, thus can be used as a 
comparator.2.1. Spacing 
 
Fig. 1. Crystal structure of dihydrofolate reductase (e.c.1.5.1.3) complexed 
with methotrexate (PDBID – 1DDS) 
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You must use single line spacing. However, when 
typing complicated mathematical text it is important to 
increase the space between the text lines in order to prevent 
sub- and superscript fonts overlapping one another and 
making your printed matter illegible. If you are using a 
desktop publishing program ensure that your auto adjust for 
interline spacing is suitably set to prevent overlapping but 
without leaving too much space. 
2.2. Molecule preparation and physicochemical analysis 
We have created 2 folate analogues (Table 1) with 
ChemBioDraw Ultra 11.0 and their 3D structure was 
generated and energy minimized using ChemBio3D Ultra 
11.0 (Table 2). Physicochemical properties of those 
compounds were calculated by Molinspiration Property 
Engine (v2014.11) internet tool. 
2.3. Molecular docking 
Molegro Virtual Docker 5.0.0 was used to generate 
docking results of the molecules with 1DDS. As for 
binding site identification, we used cavity 1 which have the 
largest volume. The docking parameter consists of max 
iterations 1500 and max population size 50. Pose 
generation with energy threshold 100.00, min: 10, quick: 
10, max: 30 and for simplex evolution max steps 300, 
neighbour distance factor was set to 1.00. 
 
 
Table 1 
Physicochemical parameters of folate analogues 
 
 
No    Molecular structure 
 
Molecular parameters 
 
 1 miLogP -1.97  
 
 
TPSA 210.55  
 atoms 33  
 MW 454.45  
 nON 13  
 nOHNH 7  
 violations 2  
 nrotb 9  
  volume 387.36  
 Methotrexate    
 2 miLogP -0.64  
 
 
TPSA 221.57  
 natoms 41  
 MW 559.54  
 nON 14  
 nOHNH 6  
 nviolations 3  
 nrotb 10  
 volume 474.59  
     
 10-N-(p-toluoyl)folic acid    
 3 miLogP -0.28  
 
 
TPSA 221.57  
 natoms 41  
 MW 624.41  
 nON 14  
 nOHNH 6  
 nviolations 3  
 nrotb 10  
 volume 475.92  
     
 10-N-(4-bromobenzoyl)folic acid    
 
TPSA: topological surface area, MW: molecular weight, nON: hydrogen bond donors, nOHNH: hydrogen bond acceptors, 
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Table 2 
Interaction of folate analogues with 1DDS 
 No Molecule Energy Rerank score ∑ H Bonds Interacting residues 
   minimized     
 1 Methotrexate -15.70 -114.60 6 Ile94,  Ile5,  Tyr100,  Arg  57, 
      Asp27 
 2 10-N-(p-toluoyl)folic acid 29.14 -129.51 5 Leu54, Arg57, Pro53, Pro55 
 3 10-N-(4-bromobenzoyl)folic 25.53 -122,74 4 Leu54, Arg57, Pro53, Pro55 
  acid      
 
 
 
 
 
Fig. 2. (a) Configurational structure of 10-N-(4’-bromobenzoyl) folic acid (blue) and methotrexate (green). (b) Configurational structure of 10-N-(p-toluoyl) 
folic acid (red) and methotrexate (green) 
3. Results and discussion 
3.1. Physicochemical analysis 
According to lipinski’s rule of 5, orally active drugs 
need to have no more than one violation of this criteria so 
that drugs could have good oral bioavailability. This 
criteria states that a drug should have molecular weight < 
500 Da; logP < 5; H Bond Donor < 5; and H bond acceptor 
< 10 [5]. From table 1, that 3 molecule including 
methotrexate has violated more than 1 of lipinski’s rule. 
This could be interpreted that those 3 molecules have 
bad bioavailability. 
Methotrexate is belong to biopharmaceutical 
classification system (BCS) class III so it has good 
solubility but low permeability. The reason methotrexate 
could have good solubility is because it has glutamate side 
chain that consists of two carboxyl groups. Those 2 folate 
analogues would likely have similar properties because 
they have a similar structure as methotrexate. 
3.2. Molecular docking 
Docking simulation of those compounds with 1DDS 
was resulted in better interaction than methotrexate. This 
result can be seen because those two molecules have lower 
rerank score. A molecule which has lower rerank score 
would need less energy so that it could bind to the protein 
and make their complexed molecule-protein more stable 
than the other the molecule which has more rerank score. 
According to table 2, compound 2 have the lowest 
rerank score but less hydrogen bond formed with protein 
and have mostly different ligand residues as methotrexate. 
This can be happened because even they both folate 
analogues, they have slightly different molecule 
configuration (Fig. 2) and causing different binding 
residues. 
As for compound 3, it has 4-bromobrnzoyl substituted 
so it has more hydrophobicity than compound 2. This can 
be seen in table 1 that compound 3 have greater value in 
miLogP and molecular weight. But even so, compound 2 
has lower rerank score than compound 3. Therefore, further 
investigation needs to be done in regard to finding the 
reason why this could happen 
4. Conclusion 
The result describes here to support that those 10-N-(4’-
bromobenzyl)folic acid and 10-N-(p-toluoyl)folic acid 
potentially has anticancer properties and even greater than 
methotrexate. However, further studies are necessary to 
fully determine its potential as anticancer and its toxicity. 
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